Priaxon AG

Priaxon, based in Munich, Germany, is a drug development company focused on small molecule therapeutics inhibiting protein-protein interactions. The company employs a unique combination of proprietary chemoinformatic tools and innovative synthetic chemistry to rationalize and accelerate the drug discovery process. Priaxon's lead projects include an inhibitor of the Mdm2-p53 interaction and a multi-action antibiotic compund. 


www.priaxon.com